CD38+CD8+ and CD38+CD4+ T Cells and IFN Gamma (+874) Polymorphism Are Associated with a Poor Virological Outcome
CD38+CD8+ and CD38+CD4+ T Cells and IFN Gamma (+874) Polymorphism Are Associated with a Poor Virological Outcome
复制标题
DOI：
10.3109/08820139.2016.1157603
复制
发表时间：
2016-04
影响因子：
2.8
通讯作者：
Paulo Germano de Carvalho;Raphael de Oliveira Rodrigues;Silvia Fernandes Ribeiro da Silva;Ilana Farias Ribeiro;Herene Barros de Miranda Lucena;Lilian Roberta Costa Martins;S. Rabenhorst;Érico Antônio Gomes de Arruda;A. Nagao-Dias
中科院分区：
文献类型：
--
作者：
Paulo Germano de Carvalho;Raphael de Oliveira Rodrigues;Silvia Fernandes Ribeiro da Silva;Ilana Farias Ribeiro;Herene Barros de Miranda Lucena;Lilian Roberta Costa Martins;S. Rabenhorst;Érico Antônio Gomes de Arruda;A. Nagao-Dias
本研究的主要目的是评估T淋巴细胞上的CD 38、IFNγ（+874 A/T）和IL-10（−1082 A/G）多态性在接受抗逆转录病毒（ARV）治疗的HIV感染患者中的应用。在巴西塞阿拉州福塔莱萨的São José de Doenças Ecciosas医院的艾滋病毒感染门诊中选择了61名患者。根据抗逆转录病毒治疗一年后的病毒载量，将患者分为两组。在病毒血症组（I组）中，观察到CD 38 + CD 4 + T细胞减少35.5%（p = 0.02），CD 38 + CD 8 + T细胞减少49.3%（p = 0.001）。在病毒血症组（II组）中，发生了37.2%的CD 38 + CD 4 + T细胞（p = 0.067）和21.4%的CD 38 + CD 8 + T细胞（p = 0.60）减少。IL-10（-1082）多态性与抗逆转录病毒治疗的反应类型之间没有关联。IFNγ基因多态性（+874T/A）中，AA型在Ⅰ组和Ⅱ组中分别占73.34%和33.3%。携带AA基因型或A等位基因且接受ARV治疗一年后无法抑制病毒载量水平的个体的相对风险分别为3.44（1.25-9.45; p = 0.014）或2.35（1.05-5.26; p = 0.027）。我们的数据表明，激活的CD 38 + CD 8 + T细胞的频率增加以及IFNγ多态性的A等位基因的存在可能有助于降低抗逆转录病毒治疗患者的病毒学抑制。
ABSTRACT The main objective of the work was to evaluate the use of CD38 on T lymphocytes, IFNγ (+874 A/T), and IL-10 (−1082 A/G) polymorphisms in HIV-infected patients under antiretroviral (ARV) therapy. Sixty-one patients were selected at the outpatient clinic for HIV infection at the Hospital São José de Doenças Infecciosas, Fortaleza, Ceará, Brazil. The patients were classified into two groups, according to viral load after one year of ARV therapy. In the aviremic group (group I), a reduction of 35.5% of CD38+CD4+ T cells was observed (p = 0.02) and 49.3% of CD38+CD8+ T cells (p = 0.001). In the viremic group (group II), a reduction of 37.2% of CD38+CD4+ T cells (p = 0.067), and 21.4% of CD38+CD8+ T cells (p = 0.60) occurred. No association was found between IL-10 (−1082) polymorphism and the type of response to ARV therapy. Regarding the gene polymorphism on IFNγ (+874 T/A), 73.34% of group I and 33.3% of group II presented the AA genotype. The relative risk of the individuals carrying AA genotype or the A allele and not being able to suppress the viral load level after one year of ARV therapy was 3.44 (1.25–9.45; p = 0.014) or 2.35 (1.05–5.26; p = 0.027), respectively. Our data suggested that an augmented frequency of activated CD38+CD8+ T cells as well as the presence of the A allele of IFNγ polymorphism could contribute to a reduced virological suppression in patients under antiretroviral therapy.